We are live on
!
Find out more
VP
venBio Partners Portfolio holdings
AUM
$281M
1-Year Est. Return
261.03%
This Fund
S&P 500
This Quarter
Est. Return
-19.24%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$117M
AUM Growth
-$116M
(-50%)
Cap. Flow
-$68.3M
Cap. Flow
% of AUM
-58.19%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
5
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$29.1M |
| 2 |
APLS
Apellis Pharmaceuticals
APLS
|
+$17.7M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$17M |
| 4 |
VRNA
Verona Pharma
VRNA
|
+$2.3M |
| 5 |
Precision BioSciences
DTIL
|
+$2.24M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AKRO
1
DELISTED
Akero Therapeutics
AKRO
| $66.8M | 56.91% |
3,150,019
-790,524
| -20% | -$17M |
|
|
2
Precision BioSciences
DTIL
$225M
| $24.2M | 20.6% |
133,597
-8,574
| -6% | -$2.24M |
|
|
APLS
3
DELISTED
Apellis Pharmaceuticals
APLS
| $13.4M | 11.45% |
501,584
-498,416
| -50% | -$17.7M |
|
|
TPTX
4
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $7.16M | 6.1% |
160,333
-547,900
| -77% | -$29.1M |
|
5
VYNE Therapeutics
VYNE
$25.5M
| $3.92M | 3.34% |
20,299
| – | – |
|
|
VRNA
6
DELISTED
Verona Pharma
VRNA
| $1.88M | 1.6% |
456,770
-418,230
| -48% | -$2.3M |
|
Similar funds
OCWP
FFP
BDA
PHC
SA
ACC
NRCM
IP